Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Advarra conducted a survey of sites, sponsors, and CROs that revealed three biggest barriers to stakeholder collaboration: communications, staffing, and technology.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

However, Vertex has a big opportunity and has over 50 authorized treatment centers activated. The company expects to share ...

In type 1 diabetes, zimislecel entered Phase 3 trials targeting 125,000 patients. Complementary therapies, including encapsulated islet cells in VX-264, are advancing, with pivotal data expected in ...

In December, Vertex's CASGEVY gained regulatory approval ... In type 1 diabetes, zimislecel entered Phase 3 trials targeting 125,000 patients. Complementary therapies, including encapsulated ...

Luckily, most streaming services these days offer a sneak peek via free trials into their cache of goodies. So whatever you’re looking to watch in 2025, these nine free trials are a great way to ...

Vertex has entered into an exclusive collaboration and license agreement with Zai Lab for the development and commercialization of povetacicept in mainland China, Hong Kong, Macau, Taiwan, and ...